Medscape InDiscussion: Breast Cancer podcast

DCIS and Low-Risk, Early-Stage Breast Cancer Part 2

Manda indietro di 15 secondi
Manda avanti di 15 secondi

Drs Lidia Schapira and Antonio Wolff resume their discussion on the current research on DCIS and other forms of lower-risk early breast cancer, and how medical oncologists can work to create an optimal treatment plan.

Relevant disclosures can be found with the episode show notes on ( The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals.


Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Tamoxifen for early breast cancer: an overview of the randomised trials

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer

Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer

NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).

FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer,%2D67%20score%20%E2%89%A5%2020%25.

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Altri episodi di "Medscape InDiscussion: Breast Cancer"